Article

Cognitive status and quality of life in patients with suspected versus proven low-grade gliomas.

Department of Neurology, University Medical Center Utrecht, The Netherlands.
Neurology (Impact Factor: 8.3). 04/2001; 56(5):618-23. DOI: 10.1212/WNL.56.5.618
Source: PubMed

ABSTRACT The preferred management of patients with suspected low-grade gliomas (S-LGG) remains controversial. The benefits of resection or radiotherapy early in the course of the disease have not been proven in terms of survival. Little is known about the effects of early therapy on quality of life (QOL) and cognitive status. The authors compared functional status, QOL, and cognitive status of patients suspected of having a LGG, in whom treatment was deferred, and patients with proven LGG (P-LGG), who underwent early surgery.
The authors recruited 24 patients suspected of having an LGG. These patients were matched with 24 patients with a histologically proven LGG and healthy control subjects for educational level, handedness, age, and gender. The two patient groups were also matched for tumor laterality, use of anticonvulsants, and interval between diagnosis and testing. Functional status was determined in both patient groups. QOL and cognitive status were compared between the three groups.
Matching criteria and functional status did not differ significantly between groups. Both patient groups scored worse on QOL scales than healthy control subjects. Unoperated patients with S-LGG scored better on most items than patients with P-LGG. Cognitive status was worse in both groups than in healthy control subjects, but, again, patients with S-LGG performed better than patients with P-LGG.
These data suggest that a wait-and-see policy in patients with S-LGG has no negative effect on cognitive performance and QOL.

0 Bookmarks
 · 
70 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: La meilleure connaissance de l'histoire spontanée des gliomes de grade II de l'Organisation mondiale de la santé (OMS), à savoir la croissance régulière, l'infiltration le long des faisceaux de substance blanche et surtout le risque de transformation anaplasique – menaçant ainsi les pronostics fonctionnel et vital – associée à une minimisation des risques de traitements, a transformé l'attitude abstentionniste « classique » en une attitude résolument thérapeutique. Le but est dorénavant de tendre vers l'élaboration de véritables stratégies thérapeutiques adaptées à chaque patient, à savoir de déterminer l'ordre et le moment de chacun des traitements (1 re voire 2 e exérèse chirurgicale, 1 re voire 2 e ligne de chimiothérapie, radiothérapie) en fonction de l'évolution tumorale (mesurée sur les images en résonance magnétiques régulières de contrôle), de l'état clinique et neuropsychologique ainsi que de l'organisation anatomofonctionnelle cérébrale individuelle (étudiée grâce aux méthodes de cartographie), afin d'éviter la transformation maligne le plus longtemps possible tout en préservant la qualité de vie, cette tumeur survenant le plus souvent chez des patients jeunes avec une vie familiale et une activité socioprofessionnelle normales.
    EMC - Neurologie. 01/2008; 5(3).
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Les tumeurs intracrâniennes, tous types confondus, sont fréquentes en neurologie. Leur incidence suit celle des accidents vasculaires cérébraux et des démences. Leur prise en charge implique un partenariat multidisciplinaire. Ainsi, à l’heure de la préservation de la qualité de vie en oncologie, la neuropsychologie prend une place croissante dans la préparation de la prise en charge des patients présentant ces tumeurs. En effet, tant dans son optique évaluative/diagnostique que du point de vue de la mise en place d’une rééducation cognitive ou d’une prise en charge comportementale, le neuropsychologue s’allie aux neuro-oncologue, neuroradiologue, anatomopathologiste, neurochirurgien, radiothérapeute… Cet article expose les grandes lignes de l’évaluation neuropsychologique, propose des pistes pour un « bilan type » basé sur l’expérience de l’auteur dans les tumeurs cérébrales primitives que sont les gliomes de bas grade et suggère une réduction de ce bilan au fur et à mesure de l’évolution et de l’aggravation de la pathologie pour préconiser en cas de métastases cérébrales un bilan minimaliste adapté.
    Psycho-Oncologie 01/2010; 4(2). · 0.08 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Tumours of the central nervous system (CNS) represent a relatively rare but serious health burden. This study provides insight into the incidence and survival patterns of gliomas in the Netherlands diagnosed in adult patients during the time period 1989–2010, with a focus on glioblastoma and low-grade gliomas. Methods Data on 21,085 gliomas (excluding grade I tumours) were obtained from the Netherlands Cancer Registry, including tumours of the CNS without pathological confirmation. We calculated the age-standardised incidence rates and the estimated annual percentage change (EAPC) for all glioma subtypes. Crude and relative survival rates were estimated using information on the vital status obtained from the Dutch Municipal Personal Records Database. Results Incidence of gliomas in adults increased over time, from 4.9 per 100,000 in 1989 to 5.9 in 2010 (EAPC 0.7%, p < 0.001). Two thirds were astrocytoma, 10% oligodendroglioma/oligoastrocytoma, 3% ependymoma and 21% were unspecified. Within the group of astrocytic tumours, the proportion of glioblastoma rose, while the proportion of anaplastic and unspecified astrocytoma decreased. Unspecified neoplasms also decreased, but this was significant only after 2005. Over the course of the study period, glioblastoma patients more often received multimodality treatment with chemotherapy concomitant and adjuvant to radiotherapy. The crude two-year survival rate of glioblastoma patients improved significantly, from 5% in the time period 1989–1994 to 15% in 2006–2010, with median survival increasing from 5.5 to 9 months. The incidence of low-grade gliomas did not change over time. Survival rates for low-grade oligodendroglial and mixed tumours show a modest improvement. Conclusions The incidence rate for the total group of gliomas slightly increased, with a decrease of anaplastic and unspecified tumours and an increase of glioblastoma. Following the introduction of combined chemoradiation, two-year survival rates for glioblastoma significantly improved. Survival improved for low-grade gliomas except for low-grade astrocytic tumours.
    European Journal of Cancer 09/2014; · 4.82 Impact Factor

Full-text (2 Sources)

Download
24 Downloads
Available from
Jun 3, 2014